Document is current

Any future updates will be listed below

Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases

Crossref DOI link: https://doi.org/10.1007/s10067-025-07559-w

Published Online: 2025-07-04

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark